Under the directive of National Health and Family Planning Commission of the People’s Republic of China (NHFPC), the Health News conducts regular public surveys on drug use quality and safety to facilitate rational drug applications by both the healthcare providers and the general public. In survey results recently published in October 2016, ASK Pharm’s Aoyiming® (奥一明® Esomeprazole Sodium for Injection) has been recognized for its drug use quality and patient safety. In addition, Aoxikang® (奥西康®, Omeprazole Sodium for Injection) has been recognized as the “2016 National Brand-Name Product”. The listing of ASK Brand and two of its products has illustrated the importance of pharmaceutical quality and drug use safety recognized by the Chinese government.
In the meantime, ASK Pharm has been consecutively awarded an “AAA Credit Enterprise” in 2016, the highest ranking recommended by the China Pharmaceutical Industry Association. This recognition has further demonstrated ASK’s strengths in corporate creditability among the national pharmaceutical industry and its consistent reputations in pharmaceutical quality and patient safety. ASK Pharm has been ranked as the “AAA Credit Enterprise” for many years; the continued trend in maintaining this prestigious national status will also help the Company in corporate expansion, product export/import, and business investment in the future.